NewAmsterdam Pharma (NAMS) | Stock Overview & Key Data
NewAmsterdam Pharma Performance Comparison
Stock Range
Today's Range
Low: $23.68
High: $24.64
on August 21, 2025
52 Week Range
Low: $14.06
High: $27.29
on April 7, 2025
on December 11, 2024
All-Time High: $27.29 on December 9, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$2.9B
EPS
-1.59
P/E Ratio (TTM)
-9.55
Forward P/E
-13.44
P/B Ratio
3.67
PEG Ratio
0.15
Div. Yield
N/A
ROE
-28.43%
Beta
-0.013
Debt to Equity
0.04
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-186.13%
Profit Margin
-258.91%
Returns and Earnings
Return on Assets (TTM)
-17.12%
Return on Equity (TTM)
-28.43%
EBITDA
$-172.6M
Net Income (TTM)
$-165.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.59
Quarterly Revenue Growth (YoY)
740.10%
Quarterly Earnings Growth (YoY)
740.06%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma NAMS | 2.86B Mid-cap | -2.90% | 8.33% | 32.04% | 31.61% | -5.86% | 50.31% | 77.10% | 61.85% |
| Vertex VRTX | 100.19B Large-cap | 1.83% | -13.31% | -8.70% | -17.92% | -2.05% | -17.41% | 41.10% | 47.23% |
| Regeneron REGN | 62.88B Large-cap | 5.69% | 9.65% | -1.07% | -14.59% | -16.36% | -50.12% | 0.33% | -0.74% |
| BridgeBio Pharma BBIO | 9.39B Mid-cap | -1.86% | 9.43% | 52.95% | 36.31% | 78.12% | 98.46% | 379.29% | 69.75% |
| Madrigal MDGL | 8.46B Mid-cap | 9.62% | 23.01% | 46.84% | 21.07% | 29.74% | 61.07% | 481.06% | 281.74% |
| Blueprint Medicines BPMC | 8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% | 12.60% | 149.54% | 73.38% |
Ownership & Short Interest
Insider Ownership
0.39%
Institutional Ownership
115.69%
Shares Short
7M
Short Ratio
8.60
Short % of Shares Outstanding
7.60%
Average 10-Day Volume
912K
Average 90-Day Volume
828K
NewAmsterdam Pharma Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in NewAmsterdam Pharma would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is NAMS's 52-week high and low?
- In the last 52 weeks, NewAmsterdam Pharma reached a high of $27.29 (on December 11, 2024) and a low of $14.06 (on April 7, 2025).
- What is the market cap and P/E ratio for NAMS?
- Curious about NewAmsterdam Pharma's size and valuation? Its market capitalization stands at 2.86B. When it comes to valuation, the P/E ratio (trailing twelve months) is -9.55, and the forward P/E (looking ahead) is -13.44.
- Does NAMS pay dividends? If so, what's the yield?
- As for dividends, NewAmsterdam Pharma isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are NewAmsterdam Pharma's main competitors or similar companies to consider before investing?
When looking at NewAmsterdam Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.41% 41.10% Regeneron
REGN62.88B Healthcare Biotechnology -50.12% 0.33% BridgeBio Pharma
BBIO9.39B Healthcare Biotechnology 98.46% 379.29% Madrigal
MDGL8.46B Healthcare Biotechnology 61.07% 481.06% Blueprint Medicines
BPMC8.37B Healthcare Biotechnology 12.60% 149.54% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for NewAmsterdam Pharma Co. N.V.? (e.g., ROE, Debt/Equity)
- To get a sense of NewAmsterdam Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -28.43%, the Debt to Equity ratio from the most recent quarter is 0.04, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for NAMS?
- Looking at NewAmsterdam Pharma's growth, its revenue over the trailing twelve months (TTM) was $64M. Compared to the same quarter last year (YoY), quarterly revenue grew by 740.10%, and quarterly earnings saw a YoY growth of 740.06%.
- How much of NAMS stock is held by insiders and institutions?
- Wondering who owns NewAmsterdam Pharma stock? Company insiders (like executives and directors) hold about 0.39% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 115.69%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.